This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.
COVID-19 Resource Center

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    Chemotherapy and Targeted Therapy for Women with HER2-negative (or unknown) Advanced Breast Cancer (beta)

    Based on guidelines from the American Society of Clinical Oncology.

    Strength
    Strong recommendation
    Moderate recommendation
    Weak recommendation
    Evidence
    High quality evidence
    Intermediate quality evidence
    Low quality evidence
    Insufficient evidence
    Refer to recommendation

    Treatment

    Endocrine Therapy in ER-positive First Relapse Metastatic Breast Cancer
    1. Endocrine therapy, rather than chemotherapy, should be offered as the standard first-line treatment for patients with hormone receptor-positive advanced/metastatic breast cancer, except for immediately life threatening disease or if there is concern regarding endocrine resistance.
    Sequential Single-agent Chemotherapy
    1. Sequential single-agent chemotherapy rather than combination therapy should be offered, although combination regimens may be considered for immediately life-threatening disease for which time may allow only one potential chance for therapy.
    Bevacizumab
    1. With regard to targeted agents, the role of bevacizumab is controversial, and this therapy should be considered (where available) with single-agent chemotherapy only when there is immediately life-threatening disease or severe symptoms, in view of improved response rates. It is recognized that there is not currently an approved indication for bevacizumab in the United States because the weight of evidence shows no significant survival benefit. Other targeted agents should not be used either in addition to, or as a replacement for, chemotherapy in this setting outside of a trial.
    First-line Chemotherapy
    1. No single agent has demonstrated superiority in the treatment of patients with advanced breast cancer, and there are several active agents appropriate for first-line chemotherapy. The evidence for efficacy is strongest for taxanes and anthracyclines. Other options include capecitabine, gemcitabine, platinum-based compounds, vinorelbine, and ixabepilone. Treatment selection should be based on previous therapy, differential toxicity, comorbid conditions, and patient preferences. Specifically, drugs for which clinical resistance has already been shown should not be reused. The evidence quality supporting the activity of a number of single agents is high, but there is insufficient evidence to support superiority of any single agent.
    2. Chemotherapy should be continued until progression of disease as tolerated because it modestly improves overall survival and substantially improves progression-free survival, but this has to be balanced against toxicity and quality of life. Short breaks, flexibility in scheduling, or a switch to endocrine therapy (in patients with hormone receptor-positive disease) may be offered to selected patients.
    3. Chemotherapy regimens should not be specifically tailored to different breast cancer subtypes (e.g. triple negative, lobular) at the present time due to the absence of evidence proving differential efficacies. In addition, in vitro chemoresistance assays should not be used to select treatment.
    Second-line and Later-line Chemotherapy
    1. Second- and later-line therapy may be of clinical benefit and should be offered as determined by previous treatments, toxicity, coexisting medical conditions, and patient choice. As with first-line treatment, no clear evidence exists for the superiority of one specific drug or regimen. Active agents include those active in first-line treatment. The quality of the evidence ranges from high to low as reported in multiple randomized trials.
    Palliative Care
    1. Palliative care should be offered throughout the continuum of care. As there are diminishing returns with later lines of chemotherapy, clinicians should also offer best supportive care without further chemotherapy as an option.
    Clinical Trials
    1. As there is no cure yet for patients with advanced breast cancer, clinicians should encourage all eligible patients to enroll onto clinical trials. This should include the option of phase II and even targeted phase I trials before all standard lines of therapy have been used, in the absence of immediately life-threatening disease. There is no strong evidence to suggest this approach might impair outcome.
    What do the icons mean?  
    Research PaperPartridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32(29):3307-29.